Takeda Healthcare Philippines, Inc. has secured two top honors at the Healthcare Asia Pharma Awards 2026, earning Most Differentiated Service of the Year – Philippines and Patient Advocacy Program of the Year – Philippines. The recognition highlights a patient access model that is helping more Filipinos complete treatment despite persistent cost and system barriers.
At the core of the company’s approach is its Patient Assistance Program (PAP), which reframes affordability as a long-term, patient-specific commitment rather than a one-time subsidy. In a healthcare landscape often defined by delayed diagnoses, fragmented referrals, and high out-of-pocket spending, the program introduces a structured framework that aligns patient contributions with their financial capacity across the full course of therapy.
Unlike standard discount schemes, PAP relies on individualized financial assessments conducted with independent third parties. Based on these evaluations, Takeda coordinates with hospitals, non-profits, and partners—including the Tzu Chi Foundation—to close funding gaps. The result is a more integrated pathway that connects diagnosis, financing, and treatment, improving the likelihood that patients stay on therapy through completion.
The impact is measurable. More than 1,300 patients in the Philippines, including those living with Hodgkin lymphoma, inflammatory bowel disease, and rare diseases, have accessed support through the program.
Many have been able to complete prescribed treatments and return to work and daily life, outcomes that remain elusive for patients facing financial strain.
Beyond direct assistance, Takeda’s model strengthens patient navigation and referral networks, particularly in underserved areas. It also complements broader policy progress, including expanded access to rare disease treatments through the Philippine National Formulary, reinforcing a more inclusive healthcare system.
